RxDoctor Payments Data

Jose Perez, DO

Family Medicine · Pembroke Pines, FLNPI 1528208691

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,610 of the $15,801 with a category attached, or 73.5%. Smith+Nephew accounts for 98.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $13,198 and has fallen 97.2% since, to $375 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,801in general payments, 2019–2025

Across 58 payments — averaging $272.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$15K
  • Johnson & Johnson$143
  • Nalu Medical, Inc.$134
  • Baxter Healthcare$25
$989,490in research payments, 2019–2025

Across 54 payments — averaging $18,324 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Celltrion, Inc.$860K
  • GSK$53K
  • Pfizer$40K
  • Novartis$20K
  • First Wave Biopharma, Inc.$16K

What the payments were for

  • Speaking & faculty fees$11,61073%
  • Travel & lodging$2,89618%
  • Food & beverage$1,2958%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew50$15,499
Johnson & Johnson6$143
Nalu Medical, Inc.1$134
Baxter Healthcare1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,801 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$3,208,207
Medicare patients
999
Services billed
5,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.267$555,708
ErtapenemErtapenem Sodium28$1,758
Mupirocin40$708
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$15,499$555,708267 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pembroke Pines

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →